`Buyout Bait' In BiotechBy
Health-care stock maven Jim McCamant can say "I told you so" about Chiron and Synergen: All year, the editor of Medical Technology Stock Letter has argued that biotechs have been so beaten down as to be bargains. Well, Swiss drug-and-chemical giant Ciba-Geigy is buying nearly half of Chiron for a steep $2.1 billion. And Amgen is acquiring Synergen for $262 million.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.